Лечение нарушений мочеиспускания у больных рассеянным склерозом

1. Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018;38(2):212-25. DOI:10.1055/s-0038-1649502
2. Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз: руководство для врачей. 5-е изд. М.: МЕДпресс-информ, 2016 [Schmidt TE, Yakhno NN. Rasseiannyi skleroz: rukovodstvo dlia vrachei. 5-e izd. Moscow: MEDpress-inform, 2016 (in Russian)].
3. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020;10(5):E305. DOI:10.3390/brainsci10050305
4. Oreja-Guevara C, Kobelt G, Berg J, et al. European multiple sclerosis platform. New insights into theburden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23(2_suppl.):166-78. DOI:10.1177/1352458517708672
5. Зырянов А.В., Баженов И.В., Филиппова Е.С., и др. Эпидемиология и характер расстройств мочеиспускания у больных рассеянным склерозом. Вестник урологии. 2020;8(2):29-36 [Zyrianov AV, Bazhenov IV, Philippova ES, et al. Epidemiology and characteristics of urinary tract dysfunction in multiple sclerosis patients. Urology Herald.
2020;8(2):29-36 (in Russian)]. DOI:10.21886/2308-6424-2020-8-2-29-36
6. Bientinesi R, Gandi C, Bassi P. Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies. Int Neurourol J. 2020;24(2):118-26. DOI:10.5213/inj.2040028.01
7. Al Dandan HB, Coote S, McClurg D. Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. Int J MS Care. 2020;22(2):91-9. DOI:10.7224/1537-2073.2019-030
8. de Sèze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915-28. DOI:10.1177/1352458506075651
9. Кузьмин И.В. Дисфункции нижних мочевых путей у больных рассеянным склерозом. Патогенез, симптоматика, диагностика. Урологические ведомости.
2023;13(2):145-56 [Kuzmin IV. Dysfunctions of the lower urinary tract in patients with multiple sclerosis. Pathogenesis, symptomatics, diagnosis. Urology Reports. 2023;13(2):145-56 (in Russian)]. DOI:10.17816/uroved529654
10. Browne C, Salmon N, Kehoe M. Bladder dysfunction and quality of life for people with multiple sclerosis. Disabil Rehabil. 2015;37(25):2350-8. DOI:10.3109/09638288.2015.1027007
11. Araki I, Matsui M, Ozawa K, et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169(4):1384-7. DOI:10.1097/01.ju.0000049644.27713.c8
12. Moussa M, Abou Chakra M, Papatsoris AG, et al. Perspectives on urological care in multiple sclerosis patients. Intractable Rare Dis Res. 2021;10(2):62-74. DOI:10.5582/irdr.2021.01029
13. Domurath B, Flachenecker P, Henze T, et al. [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis]. Nervenarzt. 2021;92(4):349-58 (in German). DOI:10.1007/s00115-020-01046-0
14. Ghasemi V, Kiani Z, Alizadeh S, et al. Prevalence of stress urinary incontinence and urge urinary incontinence in multiples sclerosis patients: a systematic review and meta-analysis. Neurol Sci. 2024. DOI:10.1007/s10072-024-07570-0
15. Касян Г.Р., Древаль Р.О., Кривобородов Г.Г., и др. Социально-экономические аспекты нейрогенных дисфункций в урологии. Урология. 2020;(5):127-32 [Kasyan GR, Dreval RO, Krivoborodov GG, et al. Socio-economic aspects of neurogenic dysfunctions in urology. Urologiia. 2020;(5):127-32 (in Russian)]. DOI:10.18565/urology.2020.5.127-132
16. Нейрогенная дисфункция нижних мочевыводящих путей. Клинические рекомендации Минздрава РФ. 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/588_2. Дата доступа: 01.07.2024 [Neurogenic dysfunction of the lower urinary tract. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://cr.minzdrav.gov.ru/schema/588_2 Accessed: 01.07.2024 (in Russian)].
17. Blok B, Castro-Diaz D, Del Popolo G, et al. Guideline of European Urological Association. 2024. Neuro-Urology. Available at: https://uroweb.org/guideline/neuro-urology. Accessed: 01.07.2024.
18. Aharony SM, Lam O, Corcos J. Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. Can Urol Assoc J.
2017;11(3-4):E110-5. DOI:10.5489/cuaj.4059
19. Medina-Polo J, Adot JM, Allué M, et al. Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. Neurourol Urodyn. 2020;39(2):762-70. DOI:10.1002/nau.24276
20. Ineichen BV, Schneider MP, Hlavica M, et al. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler. 2018;24(4):529-34. DOI:10.1177/1352458517703801
21. Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275-88. DOI:10.1038/nrurol.2016.53
22. Lúcio A, D'ancona CA, Perissinotto MC, et al. Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis. J Wound Ostomy Continence Nurs. 2016;43(4):414-9. DOI:10.1097/WON.0000000000000223
23. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 2003;20(6):374-7. DOI:10.1007/s00345-002-0309-9
24. Sapouna V, Thanopoulou S, Papriakas D, et al. Pelvic Floor Muscle Training and Its Benefits for Multiple Sclerosis Patients Suffering From Urinary Incontinence and Sexual Dysfunction. Cureus. 2023;15(10):e47086. DOI:10.7759/cureus.47086
25. Филиппова Е.С., Баженов И.В., Зырянов А.В. Лечение нейрогенной дисфункции нижних мочевыводящих путей у больных рассеянным склерозом. Эффективная фармакотерапия. 2019;15(1):22-30 [Filippova ES, Bazhenov IV, Zyryanov AV. Treatment of lower urinary tract neurogenic dysfunction in patients with multiple sclerosis. Effective Pharmacotherapy. 2019;15(1):22-30 (in Russian)].
26. Кротова Н.О., Кузьмин И.В., Улитко Т.В. Метод биологической обратной связи в лечении и реабилитации женщин с недержанием мочи. Вестник восстановительной медицины. 2020;6(100):57-65 [Krotova NO, Kuzmin IV, Ulitko TV. Biofeedback in Treatment and Rehabilitation of Urinаry Incontinence in Women. Bulletin of Rehabilitation Medicine. 2020;6(100):57-65 (in Russian)]. DOI:10.38025/2078-1962-2020-100-6-57-65
27. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432-41. DOI:10.1038/sc.2013.19
28. Кузьмин И.В., Кузьмина С.В. Антихолинергическая терапия гиперактивного мочевого пузыря: практические аспекты. РМЖ. Медицинское обозрение. 2021;5(5):273-9 [Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian)]. DOI:10.32364/2587-6821-2021-5-5-273-279
29. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753. DOI:10.1155/2011/834753
30. Proietti S, Lepri E, Lepri L, et al. Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: long term follow up. Euro Urol. Suppl. 2012;11:e468–e468a.
31. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414-21. DOI:10.1002/nau.22945
32. Zonić-Imamović M, Imamović S, Čičkušić A, et al. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. Acta Med Acad. 2019;48(3):271-7. DOI:10.5644/ama2006-124.267
33. Andretta E, Finazzi Agrò E, Calabrese M, et al. Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data. Ther Adv Urol. 2022;14:17562872221122484. DOI:10.1177/17562872221122484
34. Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergic medication in MS: Adding insult to injury? Mult Scler Relat Disord. 2012;1(4):156-61. DOI:10.1016/j.msard.2012.05.002
35. Кузьмин И.В., Слесаревская М.Н. Антихолинергическая терапия гиперактивного мочевого пузыря: геронтологические аспекты. Клиническая геронтология.
2021;27(11-12):21-34 [Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clinical Gerontologe. 2021;27(11-12):21-34 (in Russian)].
DOI:10.26347/1607-2499202111-12021-034
36. Коршунова Е.С., Коршунов М.Н., Нужный Е.П., и др. Нейрогенный гиперактивный мочевой пузырь: фокус на когнитивную функцию. Урология. 2021;(5):35-40 [Korshunova ES, Korshunov MN, Nuzhnyi EP, et al. Neurogenic overactive bladder: focus on cognitive function. Urologiia. 2021;(5):35-40 (in Russian)]. DOI:10.18565/urology.2021.5.35-40
37. Крупин В.Н., Белова А.Н. Нейрогенный мочевой пузырь и рассеянный склероз. Современные технологии в медицине. 2011;4:126-35 [Krupin VN, Belova AN. Neurogenic bladder and multiple sclerosis. Modern Technologies in Medicine. 2011;4:126-35 (in Russian)].
38. Кузьмин И.В. Персонифицированный подход к фармакотерапии гиперактивного мочевого пузыря. Урологические ведомости. 2023;13(3):267-82 [Kuzmin IV. Personalized approach to pharmacotherapy of overactive bladder. Urology Reports. 2023;13(3):267-82 (in Russian)].DOI:10.17816/uroved569404
39. Akkoc Y. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review. Spinal Cord. 2022;60(10):854-61. DOI:10.1038/s41393-022-00853-3
40. Phé V, Schneider MP, Peyronnet B, et al. Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2019;38(2):563-71. DOI:10.1002/nau.23921
41. Zachariou A, Filiponi M, Baltogiannis D, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24(6):9107-13.
42. Абдуллах Н., Белоусов И.И., Гончарова З.А., и др. Влияние регуляторных пептидов на нейрогенную дисфункцию нижних мочевых путей при рассеянном склерозе. Данные одного центра. Южно-Российский журнал терапевтической практики. 2024;5(2):79-90 [Abdallah N, Belousov II, Goncharova ZA, et al. Infuence of regulatory peptides on neurogenic lower urinary tract dysfunction in multiple sclerosis. Data of one center. South Russian Journal of Therapeutic Practice. 2024;5(2):79-90 (in Russian)].
DOI:10.21886/2712-8156-2024-5-2-79-90
43. Костенко Е.В. Применение ботулинического токсина типа A в симптоматической терапии и медицинской реабилитации пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(10):17-25 [Kostenko EV. The use of botulinum toxin type A in symptomatic therapy and medical rehabilitation of patients with multiple sclerosis. SS Korsakov Journal of Neurology and Psychiatry. 2023;123(10):17-25 (in Russian)]. DOI:10.17116/jnevro202312310117
44. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275-87. DOI:10.1016/j.eururo.2007.10.013
45. Кривобородов Г.Г., Кузьмин И.В., Ромих В.В. Абоботулотоксин А (Диспорт®) в лечении нейрогенной гиперактивности детрузора. Урология. 2023;2:122-9 [Krivoborodov GG, Kuzmin IV, Romikh VV. Аbobotulinum toxin A (Dysport®) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;2:122-9 (in Russian)].
DOI:10.18565/urology.2023.2.122-129
46. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196-200. DOI:10.1097/01.ju.0000162035.73977.1
47. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452-7. DOI:10.1002/ana.21209
48. Denys P, Castaño Botero JC, Vita Nunes RL, et al. AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Neurourol Urodyn. 2023;42(1):153-67. DOI:10.1002/nau.25062
49. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184(3):1011-6. DOI:10.1016/j.juro.2010.05.035
50. Филиппова Е.С., Баженов И.В., Зырянов А.В., и др. Оценка клинической эффективности внутрипузырных инъекций ботулинического токсина типа А в дозе 100 ЕД у пациентов с рассеянным склерозом с нейрогенной детрузорной гиперактивностью. Урологические ведомости. 2020;10(1):25-32 [Filippova ЕS, Bazhenov IV, Zyrjanov AV, et al. Clinical effectiveness of intradetrusor injections of botulinum toxin type a in dose 100 units in multiple sclerosis patients with neurogenic detrusor overactivity. Urology Reports. 2020;10(1):25-32 (in Russian)]. DOI:10.17816/uroved10125-32
51. Bensmail D, Karam P, Forestier A, et al. Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins (Basel). 2023;15(4):280. DOI:10.3390/toxins15040280
52. Joussain C, Popoff M, Phé V, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn. 2018;37(2):799-806. DOI:10.1002/nau.23352
53. Кузьмин И.В., Слесаревская М.Н., Амдий Р.Э., и др. Длительная ботулинотерапия гиперактивного мочевого пузыря: мифы и реальность. Урологические ведомости. 2022;12(1):71-84 [Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology Reports. 2022;12(1):71-84 (in Russian)]. DOI:10.17816/uroved104335
54. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335-40. DOI:10.1080/00365590601068835
55. Rahnama'i MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler. 2020;26(11):1274-80. DOI:10.1177/1352458519894714
56. Canbaz Kabay S, Kabay S, Mestan E, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017;36(1):104-10. DOI:10.1002/nau.22868
57. Zonić-Imamović M, Imamović S, Čičkušić A, et al. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. Acta Med Acad. 2019;48(3):271-7. DOI:10.5644/ama2006-124.267
58. Majdinasab N, Orakifar N, Kouti L, et al. Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis. Front Neurosci. 2023;17:1107886. DOI:10.3389/fnins.2023.1107886
59. de Sèze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306-11. DOI:10.1002/nau.20958
60. Sapouna V, Zikopoulos A, Thanopoulou S, et al. Posterior Tibial Nerve Stimulation for the Treatment of Detrusor Overactivity in Multiple Sclerosis Patients: A Narrative Review. J Pers Med. 2024;14(4):355. DOI:10.3390/jpm14040355
61. Guitynavard F, Mirmosayyeb O, Razavi ERV, et al. Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Mult Scler Relat Disord. 2022;58:103392. DOI:10.1016/j.msard.2021.103392
62. Tahmasbi F, Hosseini S, Hajebrahimi S, et al. Efficacy of Tibial Nerve Stimulation in Neurogenic Lower Urinary Tract Dysfunction Among Patients with Multiple Sclerosis: A Systematic Review and Meta-analysis. Urol Res Pract. 2023;49(2):100-11. DOI:10.5152/tud.2023.22241
63. Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865-74. DOI:10.1016/j.eururo.2010.09.024
64. Averbeck MA, Moreno-Palacios J, Aparicio A. Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction? Int Braz J Urol.
2020;46(6):891-901. DOI:10.1590/S1677-5538.IBJU.2020.99.10
65. Смирнов Д.С., Пасхин Д.Л., Декопов А.В., и др. Опыт использования эпидуральной и сакральной нейростимуляции в лечении расстройств мочеиспускания при рассеянном склерозе. Российский нейрохирургический журнал им. проф. А.Л. Поленова. 2023;15(S1):306 [Smirnov DS, Pasxin DL, Dekopov AV, et al. Experience of using epidural and sacral neurostimulation in the treatment of urinary disorders in multiple sclerosis. Russian Neurosurgical Journal named after professor AL Polenov. 2023;15(S1):306 (in Russian)].
66. Centonze D, Petta F, Versace V, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler. 2007;13(2):269-71. DOI:10.1177/1352458506070729
67. Khavari R, Tran K, Helekar SA, et al. Noninvasive, Individualized Cortical Modulation Using Transcranial Rotating Permanent Magnet Stimulator for Voiding Dysfunction in Women with Multiple Sclerosis: A Pilot Trial. J Urol. 2022;207(3):657-68. DOI:10.1097/JU.0000000000002297
68. O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153(4):1114-6.
69. Kilicarslan H, Ayan S, Vuruskan H, et al. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol. 2006;38(3-4):537-41.
DOI:10.1007/s11255-006-0071-9
70. Станкович Е.Ю., Борисов В.В., Демина Т.Л. Тамсулозин в лечении детрузорно-сфинктерной диссинергии мочевого пузыря у больных рассеянным склерозом. Урология. 2004;(4):48-51 [Stankovich EYu, Borisov VV, Demina TL. Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis. Urologiia. 2004;(4):48-51 (in Russian)].
71. Moon KH, Park CH, Jung HC, et al. A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder. Low Urin Tract Symptoms. 2015;7(1):27-31. DOI:10.1111/luts.12044
72. Schneider MP, Tornic J, Sýkora R, et al. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2019;38(6):1482-91. DOI:10.1002/nau.24039
73. Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn. 1993;12(2):163-70. DOI:10.1002/nau.1930120210
74. Mukouyama H, Nakasone K, Shimabukuro H, et al. [Effect of distigmine at 5 mg daily in patients with detrusor underactivity]. Nihon Hinyokika Gakkai Zasshi. 2014;105(1):10-6 (in Japanese). DOI:10.5980/jpnjurol 
75. Bayrak Ö, Dmochowski RR. Underactive bladder: A review of the current treatment concepts. Turk J Urol. 2019;45(6):401-9. DOI:10.5152/tud.2019.37659
76. Амдий Р.Э., Аль-Шукри С.Х., Кузьмин И.В., и др. Экстракорпоральная магнитная стимуляция в урологии. Урологические ведомости. 2021;11(4):345-53 [Amdiy RE, Al-Shukri SK, Kuzmin IV, et al. Extracorporeal magnetic stimulation in urology. Urology Reports. 2021;11(4):345-53 (in Russian)]. DOI:10.17816/uroved84474
77. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919-22.
DOI:10.1016/s0022-5347(17)42717-0
78. Gallien P, Reymann JM, Amarenco G, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670-6. DOI:10.1136/jnnp.2004.045765
79. Мазо Е.Б., Кривобородов Г.Г., Ефремов Н.С. Применение ботулинического токсина типа А при лечении нарушений опорожнения мочевого пузыря у неврологических больных. Терапевтический архив. 2008;80(10):49-52 [Mazo ЕВ, Krivoborodov GG, Efremov NS. Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility. Terapevticheskii Arkhiv (Ter. Arkh.). 2008;80(10):49-52 (in Russian)].
80. Tsai SJ, Ying TH, Huang YH, et al. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90(5):832-6. DOI:10.1016/j.apmr.2008.10.023
81. Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014(5):CD004927.
82. Castel-Lacanal E, Gamé X, De Boissezon X, et al. Impact of intermittent catheterization on the quality of life of multiple sclerosis patients. World J Urol. 2013;31(6):1445-50. DOI:10.1007/s00345-012-1017-8
83. Tornic J, Sartori AM, Gajewski JB, et al. Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2018;37(8):2315-22. DOI:10.1002/nau.23733
84. Vahter L, Zopp I, Kreegipuu M, et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler. 2009;15(3):379-84. DOI:10.1177/1352458508098599
85. Mahajan ST, Frasure HE, Marrie RA. The prevalence of urinary catheterization in women and men with multiple sclerosis. J Spinal Cord Med. 2013;36(6):632-7. DOI:10.1179/2045772312Y.0000000084

________________________________________________

1. Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018;38(2):212-25. DOI:10.1055/s-0038-1649502
2. Schmidt TE, Yakhno NN. Rasseiannyi skleroz: rukovodstvo dlia vrachei. 5-e izd. Moscow: MEDpress-inform, 2016 (in Russian).
3. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020;10(5):E305. DOI:10.3390/brainsci10050305
4. Oreja-Guevara C, Kobelt G, Berg J, et al. European multiple sclerosis platform. New insights into theburden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler. 2017;23(2_suppl.):166-78. DOI:10.1177/1352458517708672
5. Zyrianov AV, Bazhenov IV, Philippova ES, et al. Epidemiology and characteristics of urinary tract dysfunction in multiple sclerosis patients. Urology Herald. 2020;8(2):29-36 (in Russian). DOI:10.21886/2308-6424-2020-8-2-29-36
6. Bientinesi R, Gandi C, Bassi P. Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies. Int Neurourol J. 2020;24(2):118-26. DOI:10.5213/inj.2040028.01
7. Al Dandan HB, Coote S, McClurg D. Prevalence of Lower Urinary Tract Symptoms in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. Int J MS Care. 2020;22(2):91-9. DOI:10.7224/1537-2073.2019-030
8. de Sèze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915-28. DOI:10.1177/1352458506075651
9. Kuzmin IV. Dysfunctions of the lower urinary tract in patients with multiple sclerosis. Pathogenesis, symptomatics, diagnosis. Urology Reports. 2023;13(2):145-56 (in Russian). DOI:10.17816/uroved529654
10. Browne C, Salmon N, Kehoe M. Bladder dysfunction and quality of life for people with multiple sclerosis. Disabil Rehabil. 2015;37(25):2350-8. DOI:10.3109/09638288.2015.1027007
11. Araki I, Matsui M, Ozawa K, et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169(4):1384-7. DOI:10.1097/01.ju.0000049644.27713.c8
12. Moussa M, Abou Chakra M, Papatsoris AG, et al. Perspectives on urological care in multiple sclerosis patients. Intractable Rare Dis Res. 2021;10(2):62-74. DOI:10.5582/irdr.2021.01029
13. Domurath B, Flachenecker P, Henze T, et al. [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis]. Nervenarzt. 2021;92(4):349-58 (in German). DOI:10.1007/s00115-020-01046-0
14. Ghasemi V, Kiani Z, Alizadeh S, et al. Prevalence of stress urinary incontinence and urge urinary incontinence in multiples sclerosis patients: a systematic review and meta-analysis. Neurol Sci. 2024. DOI:10.1007/s10072-024-07570-0
15. Kasyan GR, Dreval RO, Krivoborodov GG, et al. Socio-economic aspects of neurogenic dysfunctions in urology. Urologiia. 2020;(5):127-32 (in Russian). DOI:10.18565/urology.2020.5.127-132
16. Neurogenic dysfunction of the lower urinary tract. Clinical recommendations of the Ministry of Health of the Russian Federation. 2020. Available at: https://cr.minzdrav.gov.ru/schema/588_2 Accessed: 01.07.2024 (in Russian).
17. Blok B, Castro-Diaz D, Del Popolo G, et al. Guideline of European Urological Association. 2024. Neuro-Urology. Available at: https://uroweb.org/guideline/neuro-urology. Accessed: 01.07.2024.
18. Aharony SM, Lam O, Corcos J. Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. Can Urol Assoc J.
2017;11(3-4):E110-5. DOI:10.5489/cuaj.4059
19. Medina-Polo J, Adot JM, Allué M, et al. Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. Neurourol Urodyn. 2020;39(2):762-70. DOI:10.1002/nau.24276
20. Ineichen BV, Schneider MP, Hlavica M, et al. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler. 2018;24(4):529-34. DOI:10.1177/1352458517703801
21. Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275-88. DOI:10.1038/nrurol.2016.53
22. Lúcio A, D'ancona CA, Perissinotto MC, et al. Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis. J Wound Ostomy Continence Nurs. 2016;43(4):414-9. DOI:10.1097/WON.0000000000000223
23. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 2003;20(6):374-7. DOI:10.1007/s00345-002-0309-9
24. Sapouna V, Thanopoulou S, Papriakas D, et al. Pelvic Floor Muscle Training and Its Benefits for Multiple Sclerosis Patients Suffering From Urinary Incontinence and Sexual Dysfunction. Cureus. 2023;15(10):e47086. DOI:10.7759/cureus.47086
25. Filippova ES, Bazhenov IV, Zyryanov AV. Treatment of lower urinary tract neurogenic dysfunction in patients with multiple sclerosis. Effective Pharmacotherapy. 2019;15(1):22-30 (in Russian).
26. Krotova NO, Kuzmin IV, Ulitko TV. Biofeedback in Treatment and Rehabilitation of Urinаry Incontinence in Women. Bulletin of Rehabilitation Medicine. 2020;6(100):57-65 (in Russian). DOI:10.38025/2078-1962-2020-100-6-57-65
27. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432-41. DOI:10.1038/sc.2013.19
28. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5):273-9 (in Russian).
DOI:10.32364/2587-6821-2021-5-5-273-279
29. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753. DOI:10.1155/2011/834753
30. Proietti S, Lepri E, Lepri L, et al. Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: long term follow up. Euro Urol. Suppl. 2012;11:e468–e468a.
31. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414-21. DOI:10.1002/nau.22945
32. Zonić-Imamović M, Imamović S, Čičkušić A, et al. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. Acta Med Acad. 2019;48(3):271-7. DOI:10.5644/ama2006-124.267
33. Andretta E, Finazzi Agrò E, Calabrese M, et al. Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data. Ther Adv Urol. 2022;14:17562872221122484. DOI:10.1177/17562872221122484
34. Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergic medication in MS: Adding insult to injury? Mult Scler Relat Disord. 2012;1(4):156-61. DOI:10.1016/j.msard.2012.05.002
35. Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clinical Gerontologe. 2021;27(11-12):21-34 (in Russian).
DOI:10.26347/1607-2499202111-12021-034
36. Korshunova ES, Korshunov MN, Nuzhnyi EP, et al. Neurogenic overactive bladder: focus on cognitive function. Urologiia. 2021;(5):35-40 (in Russian).
DOI:10.18565/urology.2021.5.35-40
37. Krupin VN, Belova AN. Neurogenic bladder and multiple sclerosis. Modern Technologies in Medicine. 2011;4:126-35 (in Russian).
38. Kuzmin IV. Personalized approach to pharmacotherapy of overactive bladder. Urology Reports. 2023;13(3):267-82 (in Russian).DOI:10.17816/uroved569404
39. Akkoc Y. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review. Spinal Cord. 2022;60(10):854-61. DOI:10.1038/s41393-022-00853-3
40. Phé V, Schneider MP, Peyronnet B, et al. Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2019;38(2):563-71. DOI:10.1002/nau.23921
41. Zachariou A, Filiponi M, Baltogiannis D, et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol. 2017;24(6):9107-13.
42. Abdallah N, Belousov II, Goncharova ZA, et al. Infuence of regulatory peptides on neurogenic lower urinary tract dysfunction in multiple sclerosis. Data of one center. South Russian Journal of Therapeutic Practice. 2024;5(2):79-90 (in Russian). DOI:10.21886/2712-8156-2024-5-2-79-90
43. Kostenko EV. The use of botulinum toxin type A in symptomatic therapy and medical rehabilitation of patients with multiple sclerosis. SS Korsakov Journal of Neurology and Psychiatry. 2023;123(10):17-25 (in Russian). DOI:10.17116/jnevro202312310117
44. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275-87. DOI:10.1016/j.eururo.2007.10.013
45. Krivoborodov GG, Kuzmin IV, Romikh VV. Аbobotulinum toxin A (Dysport®) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;2:122-9 (in Russian). DOI:10.18565/urology.2023.2.122-129
46. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196-200. DOI:10.1097/01.ju.0000162035.73977.1
47. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452-7. DOI:10.1002/ana.21209
48. Denys P, Castaño Botero JC, Vita Nunes RL, et al. AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). Neurourol Urodyn. 2023;42(1):153-67. DOI:10.1002/nau.25062
49. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184(3):1011-6. DOI:10.1016/j.juro.2010.05.035
50. Filippova ЕS, Bazhenov IV, Zyrjanov AV, et al. Clinical effectiveness of intradetrusor injections of botulinum toxin type a in dose 100 units in multiple sclerosis patients with neurogenic detrusor overactivity. Urology Reports. 2020;10(1):25-32 (in Russian). DOI:10.17816/uroved10125-32
51. Bensmail D, Karam P, Forestier A, et al. Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study. Toxins (Basel). 2023;15(4):280. DOI:10.3390/toxins15040280
52. Joussain C, Popoff M, Phé V, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn. 2018;37(2):799-806. DOI:10.1002/nau.23352
53. Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology Reports. 2022;12(1):71-84 (in Russian). DOI:10.17816/uroved104335
54. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335-40. DOI:10.1080/00365590601068835
55. Rahnama'i MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler. 2020;26(11):1274-80. DOI:10.1177/1352458519894714
56. Canbaz Kabay S, Kabay S, Mestan E, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017;36(1):104-10. DOI:10.1002/nau.22868
57. Zonić-Imamović M, Imamović S, Čičkušić A, et al. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. Acta Med Acad. 2019;48(3):271-7. DOI:10.5644/ama2006-124.267
58. Majdinasab N, Orakifar N, Kouti L, et al. Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis. Front Neurosci. 2023;17:1107886. DOI:10.3389/fnins.2023.1107886
59. de Sèze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306-11. DOI:10.1002/nau.20958
60. Sapouna V, Zikopoulos A, Thanopoulou S, et al. Posterior Tibial Nerve Stimulation for the Treatment of Detrusor Overactivity in Multiple Sclerosis Patients: A Narrative Review. J Pers Med. 2024;14(4):355. DOI:10.3390/jpm14040355
61. Guitynavard F, Mirmosayyeb O, Razavi ERV, et al. Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Mult Scler Relat Disord. 2022;58:103392. DOI:10.1016/j.msard.2021.103392
62. Tahmasbi F, Hosseini S, Hajebrahimi S, et al. Efficacy of Tibial Nerve Stimulation in Neurogenic Lower Urinary Tract Dysfunction Among Patients with Multiple Sclerosis: A Systematic Review and Meta-analysis. Urol Res Pract. 2023;49(2):100-11. DOI:10.5152/tud.2023.22241
63. Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865-74. DOI:10.1016/j.eururo.2010.09.024
64. Averbeck MA, Moreno-Palacios J, Aparicio A. Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction? Int Braz J Urol.
2020;46(6):891-901. DOI:10.1590/S1677-5538.IBJU.2020.99.10
65. Smirnov DS, Pasxin DL, Dekopov AV, et al. Experience of using epidural and sacral neurostimulation in the treatment of urinary disorders in multiple sclerosis. Russian Neurosurgical Journal named after professor AL Polenov. 2023;15(S1):306 (in Russian).
66. Centonze D, Petta F, Versace V, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler. 2007;13(2):269-71. DOI:10.1177/1352458506070729
67. Khavari R, Tran K, Helekar SA, et al. Noninvasive, Individualized Cortical Modulation Using Transcranial Rotating Permanent Magnet Stimulator for Voiding Dysfunction in Women with Multiple Sclerosis: A Pilot Trial. J Urol. 2022;207(3):657-68. DOI:10.1097/JU.0000000000002297
68. O'Riordan JI, Doherty C, Javed M, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153(4):1114-6.
69. Kilicarslan H, Ayan S, Vuruskan H, et al. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol. 2006;38(3-4):537-41.
DOI:10.1007/s11255-006-0071-9
70. Stankovich EYu, Borisov VV, Demina TL. Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis. Urologiia.
2004;(4):48-51 (in Russian).
71. Moon KH, Park CH, Jung HC, et al. A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder. Low Urin Tract Symptoms. 2015;7(1):27-31. DOI:10.1111/luts.12044
72. Schneider MP, Tornic J, Sýkora R, et al. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2019;38(6):1482-91. DOI:10.1002/nau.24039
73. Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn. 1993;12(2):163-70. DOI:10.1002/nau.1930120210
74. Mukouyama H, Nakasone K, Shimabukuro H, et al. [Effect of distigmine at 5 mg daily in patients with detrusor underactivity]. Nihon Hinyokika Gakkai Zasshi. 2014;105(1):10-6 (in Japanese). DOI:10.5980/jpnjurol 
75. Bayrak Ö, Dmochowski RR. Underactive bladder: A review of the current treatment concepts. Turk J Urol. 2019;45(6):401-9. DOI:10.5152/tud.2019.37659
76. Amdiy RE, Al-Shukri SK, Kuzmin IV, et al. Extracorporeal magnetic stimulation in urology. Urology Reports. 2021;11(4):345-53 (in Russian). DOI:10.17816/uroved84474
77. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919-22.
DOI:10.1016/s0022-5347(17)42717-0
78. Gallien P, Reymann JM, Amarenco G, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670-6. DOI:10.1136/jnnp.2004.045765
79. Mazo ЕВ, Krivoborodov GG, Efremov NS. Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility. Terapevticheskii Arkhiv (Ter. Arkh.). 2008;80(10):49-52 (in Russian).
80. Tsai SJ, Ying TH, Huang YH, et al. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90(5):832-6. DOI:10.1016/j.apmr.2008.10.023
81. Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014(5):CD004927.
82. Castel-Lacanal E, Gamé X, De Boissezon X, et al. Impact of intermittent catheterization on the quality of life of multiple sclerosis patients. World J Urol. 2013;31(6):1445-50. DOI:10.1007/s00345-012-1017-8
83. Tornic J, Sartori AM, Gajewski JB, et al. Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). Neurourol Urodyn. 2018;37(8):2315-22. DOI:10.1002/nau.23733
84. Vahter L, Zopp I, Kreegipuu M, et al. Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler. 2009;15(3):379-84. DOI:10.1177/1352458508098599
85. Mahajan ST, Frasure HE, Marrie RA. The prevalence of urinary catheterization in women and men with multiple sclerosis. J Spinal Cord Med. 2013;36(6):632-7. DOI:10.1179/2045772312Y.0000000084

И.В. Кузьмин*¹, С.В. Кузьмина<sup>1,2

1</sup>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
²ГБУЗ ЛО «Токсовская клиническая межрайонная больница», пос. Токсово, Россия
*kuzminigor@mail.ru

________________________________________________

Igor V. Kuzmin*¹, Svetlana V. Kuzmina<sup>1,2

1</sup>Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
²Toksovo Clinical Interdistrict Hospital, Toksovo, Russia
*kuzminigor@mail.ru